HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Risa Kakuta Selected Research

Pemphigus (Pemphigus Vulgaris)

2/2019Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Risa Kakuta Research Topics

Disease

1Bullous Pemphigoid (Pemphigoid)
02/2019
1Pemphigus (Pemphigus Vulgaris)
02/2019
1Eccrine Porocarcinoma
09/2015
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
05/2014
1Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)
05/2014
1Herpes Zoster
02/2014
1Ulcer
02/2014
1Rheumatoid Arthritis
02/2014

Drug/Important Bio-Agent (IBA)

1Rituximab (Mabthera)FDA Link
02/2019
1AutoantibodiesIBA
02/2019
1Immunoglobulin G (IgG)IBA
02/2019
1Epirubicin (Ellence)FDA LinkGeneric
09/2015
1Carboplatin (JM8)FDA LinkGeneric
09/2015
1Cyclosporine (Ciclosporin)FDA LinkGeneric
05/2014
1SteroidsIBA
05/2014
1Methotrexate (Mexate)FDA LinkGeneric
02/2014

Therapy/Procedure

1Drug Therapy (Chemotherapy)
09/2015